<p>Assenagon Asset Management S.A. 在第三季度減少了對 Emergent Biosolutions Inc.（紐約證券交易所代碼：EBS - 免費報告）的持股比例，降幅為 81.8%，根據該公司最近向證券交易委員會的披露。這家機構投資者在該季度出售了 253,236 股後，持有 56,455 股該生物製藥公司的股票。Assenagon Asset Management S.A. 在最近的報告期末持有的 Emergent Biosolutions 的股份約佔 0.11%，價值 498,000 美元。</p>
<p>獲取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
<ul>
<li>在美聯儲降息後值得關注的 3 只小盤股</li>
</ul>
<p>其他幾家機構投資者和對沖基金也買賣了 EBS 的股票。Vanguard Personalized Indexing Management LLC 在第二季度增加了對 Emergent Biosolutions 的持股，增幅為 14.1%。Vanguard Personalized Indexing Management LLC 目前持有 17,824 股該生物製藥公司的股票，價值 114,000 美元，此前在上個季度又購買了 2,204 股。Cetera Investment Advisers 在第二季度將其在 Emergent Biosolutions 的持股增加了 0.7%。Cetera Investment Advisers 目前持有 358,952 股該生物製藥公司的股票，價值 2,290,000 美元，此前在上個季度又收購了 2,671 股。EP Wealth Advisors LLC 在第一季度將其在 Emergent Biosolutions 的持股增加了 33.1%。EP Wealth Advisors LLC 目前持有 15,249 股該生物製藥公司的股票，價值 74,000 美元，此前在上個季度又收購了 3,790 股。Legal &amp; General Group Plc 在第二季度收購了 Emergent Biosolutions 的新股份，價值約 31,000 美元。最後，Ameritas Investment Partners Inc. 在第二季度購買了 Emergent Biosolutions 的新股份，價值約 35,000 美元。機構投資者持有該公司 78.40% 的股票。</p>
<h2>Emergent Biosolutions 股票表現</h2>
<p>EBS 股票在週五開盤價為 12.63 美元。Emergent Biosolutions Inc. 的一年低點為 4.02 美元，一年高點為 13.41 美元。該公司的市值為 6.6333 億美元，市盈率為 9.72，貝塔值為 2.32。該公司的債務與股本比率為 1.14，流動比率為 5.76，速動比率為 3.15。該股票的 50 日移動平均價格為 10.94 美元，200 日移動平均價格為 8.86 美元。</p>
<ul>
<li>大幅反彈即將來臨？3 只分析師推薦的股票值得密切關注</li>
</ul>
<p>Emergent Biosolutions（紐約證券交易所代碼：EBS - 獲取免費報告）最近在 1 月 9 日（星期二）發佈了季度財報。這家生物製藥公司報告的每股收益（EPS）為（1.27 美元）。Emergent Biosolutions 的淨利潤率為 9.62%，股本回報率為 20.85%。該公司在該季度的收入為 2.225 億美元。平均而言，股票分析師預測 Emergent Biosolutions Inc. 在當前年度將發佈-0.63 的每股收益。</p>
<h2>Emergent Biosolutions 的內部交易</h2>
<p>在相關消息中，董事 Ronald Richard 於 12 月 5 日（星期五）出售了 21,984 股該股票，交易平均價格為 11.97 美元，總交易額為 263,148.48 美元。交易完成後，該董事直接持有 98,417 股公司的股票，估值約為 1,178,051.49 美元。這代表其持股比例減少了 18.26%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，執行副總裁 Coleen Glessner 於 10 月 7 日（星期二）出售了 30,608 股 Emergent Biosolutions 股票，交易平均價格為 10.00 美元，總價值為 306,080.00 美元。交易完成後，該執行副總裁直接持有公司 144,319 股，估值約為 1,443,190 美元。該交易使其持股比例減少了 17.50%。有關此交易的更多細節可在官方 SEC 披露中找到。公司內部人士持有 1.20% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>在市場輪換持續的情況下，關注這 4 只超買股票</li>
</ul>
<p>一些研究分析師最近對該股票發佈了報告。Zacks Research 在 10 月 24 日（星期五）的研究報告中將 Emergent Biosolutions 的股票評級上調至 “持有”。HC Wainwright 在 12 月 16 日（星期二）的研究報告中重申了 “買入” 評級，並設定了 15.00 美元的目標價。Weiss Ratings 在週一的研究報告中重新發布了對 Emergent Biosolutions 的 “持有（c-）” 評級。最後，Wall Street Zen 在 11 月 30 日（星期日）的研究報告中將 Emergent Biosolutions 的評級從 “買入” 上調至 “強力買入”。一位研究分析師對該股票給予了買入評級，兩位分析師對該股票給予了持有評級。根據 MarketBeat.com，該公司目前的平均評級為 “持有”，平均目標價為 15.00 美元。</p>
<p><strong>查看我們關於 EBS 的最新報告</strong></p>
<h2>關於 Emergent Biosolutions</h2>
<p>（免費報告）</p>
<p>Emergent BioSolutions 是一家全球性的專業生物製藥公司，專注於開發、生產和商業化應對公共衞生威脅的醫療對策和專業產品。該公司的產品組合包括疫苗、抗體療法和旨在保護人們免受生物、化學和新興傳染病威脅的重症護理產品。Emergent 與政府機構（包括美國國防部和生物醫學高級研究與發展局（BARDA））建立了長期合作關係，以支持國家應急準備計劃。</p>
<p>Emergent 產品線中的關鍵商業產品包括 BioThrax（炭疽疫苗）、ACAM2000（天花疫苗）和 Vaxchora（霍亂疫苗），以及治療性產品如 Anthrasil（炭疽免疫球蛋白）和用於阿片類藥物過量逆轉的納洛酮鼻噴霧劑 Narcan。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Emergent Biosolutions</li>
<li>在 1 月 1 日前投資 1000 美元於此股票 [不是 NVDA]</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓為戰爭做準備</li>
<li>奇特的水晶金屬性能超越硅達 100 倍</li>
<li>來自奇怪新 “AI 燃料” 的 33000% 繁榮？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元於 Emergent Biosolutions 嗎？</h2>
<p>在你考慮 Emergent Biosolutions 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Emergent Biosolutions 並不在名單上。</p>
<p>雖然 Emergent Biosolutions 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Assenagon Asset Management S.A. 在第三季度將其在 Emergent Biosolutions Inc. 的持股減少了 81.8%，目前持有 56,455 股，價值 498,000 美元。其他機構投資者，包括先鋒集團和 Cetera，也調整了他們在 EBS 的持倉。Emergent Biosolutions 的股票開盤價為 12.63 美元，市值為 6.6333 億美元。分析師對該股票的評級不一，有些將其升級為 “強力買入”</p>

<p>Assenagon Asset Management S.A. lessened its stake in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 81.8% in the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 56,455 shares of the biopharmaceutical company's stock after selling 253,236 shares during the quarter. Assenagon Asset Management S.A. owned about 0.11% of Emergent Biosolutions worth $498,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在第三季度減少了對 Emergent Biosolutions Inc.（紐約證券交易所代碼：EBS - 免費報告）的持股比例，降幅為 81.8%，根據該公司最近向證券交易委員會的披露。這家機構投資者在該季度出售了 253,236 股後，持有 56,455 股該生物製藥公司的股票。Assenagon Asset Management S.A. 在最近的報告期末持有的 Emergent Biosolutions 的股份約佔 0.11%，價值 498,000 美元。</p>
</div><p>Get <strong>Emergent Biosolutions</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在美聯儲降息後值得關注的 3 只小盤股</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also bought and sold shares of EBS. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Emergent Biosolutions by 14.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 17,824 shares of the biopharmaceutical company's stock worth $114,000 after buying an additional 2,204 shares in the last quarter. Cetera Investment Advisers grew its position in Emergent Biosolutions by 0.7% during the 2nd quarter. Cetera Investment Advisers now owns 358,952 shares of the biopharmaceutical company's stock worth $2,290,000 after acquiring an additional 2,671 shares during the last quarter. EP Wealth Advisors LLC grew its position in Emergent Biosolutions by 33.1% during the 1st quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 3,790 shares during the last quarter. Legal &amp; General Group Plc acquired a new position in Emergent Biosolutions in the 2nd quarter worth about $31,000. Finally, Ameritas Investment Partners Inc. bought a new position in Emergent Biosolutions in the second quarter valued at about $35,000. Institutional investors own 78.40% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金也買賣了 EBS 的股票。Vanguard Personalized Indexing Management LLC 在第二季度增加了對 Emergent Biosolutions 的持股，增幅為 14.1%。Vanguard Personalized Indexing Management LLC 目前持有 17,824 股該生物製藥公司的股票，價值 114,000 美元，此前在上個季度又購買了 2,204 股。Cetera Investment Advisers 在第二季度將其在 Emergent Biosolutions 的持股增加了 0.7%。Cetera Investment Advisers 目前持有 358,952 股該生物製藥公司的股票，價值 2,290,000 美元，此前在上個季度又收購了 2,671 股。EP Wealth Advisors LLC 在第一季度將其在 Emergent Biosolutions 的持股增加了 33.1%。EP Wealth Advisors LLC 目前持有 15,249 股該生物製藥公司的股票，價值 74,000 美元，此前在上個季度又收購了 3,790 股。Legal &amp; General Group Plc 在第二季度收購了 Emergent Biosolutions 的新股份，價值約 31,000 美元。最後，Ameritas Investment Partners Inc. 在第二季度購買了 Emergent Biosolutions 的新股份，價值約 35,000 美元。機構投資者持有該公司 78.40% 的股票。</p>
</div><h2>Emergent Biosolutions Stock Performance</h2>
<div class="lb-trans"><h2>Emergent Biosolutions 股票表現</h2>
</div><p>EBS stock opened at $12.63 on Friday. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.41. The company has a market cap of $663.33 million, a P/E ratio of 9.72 and a beta of 2.32. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.76 and a quick ratio of 3.15. The stock's fifty day moving average price is $10.94 and its 200-day moving average price is $8.86.</p>
<div class="lb-trans"><p>EBS 股票在週五開盤價為 12.63 美元。Emergent Biosolutions Inc. 的一年低點為 4.02 美元，一年高點為 13.41 美元。該公司的市值為 6.6333 億美元，市盈率為 9.72，貝塔值為 2.32。該公司的債務與股本比率為 1.14，流動比率為 5.76，速動比率為 3.15。該股票的 50 日移動平均價格為 10.94 美元，200 日移動平均價格為 8.86 美元。</p>
</div><ul>
<li>Big Rallies Brewing? 3 Analyst Favorites to Watch Closely</li>
</ul>
<div class="lb-trans"><ul>
<li>大幅反彈即將來臨？3 只分析師推薦的股票值得密切關注</li>
</ul>
</div><p>Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. Emergent Biosolutions had a net margin of 9.62% and a return on equity of 20.85%. The business had revenue of $222.50 million for the quarter. On average, equities analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Emergent Biosolutions（紐約證券交易所代碼：EBS - 獲取免費報告）最近在 1 月 9 日（星期二）發佈了季度財報。這家生物製藥公司報告的每股收益（EPS）為（1.27 美元）。Emergent Biosolutions 的淨利潤率為 9.62%，股本回報率為 20.85%。該公司在該季度的收入為 2.225 億美元。平均而言，股票分析師預測 Emergent Biosolutions Inc. 在當前年度將發佈-0.63 的每股收益。</p>
</div><h2>Insider Transactions at Emergent Biosolutions</h2>
<div class="lb-trans"><h2>Emergent Biosolutions 的內部交易</h2>
</div><p>In related news, Director Ronald Richard sold 21,984 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $11.97, for a total transaction of $263,148.48. Following the completion of the transaction, the director directly owned 98,417 shares of the company's stock, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, EVP Coleen Glessner sold 30,608 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $10.00, for a total value of $306,080.00. Following the completion of the sale, the executive vice president directly owned 144,319 shares in the company, valued at approximately $1,443,190. The trade was a 17.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Ronald Richard 於 12 月 5 日（星期五）出售了 21,984 股該股票，交易平均價格為 11.97 美元，總交易額為 263,148.48 美元。交易完成後，該董事直接持有 98,417 股公司的股票，估值約為 1,178,051.49 美元。這代表其持股比例減少了 18.26%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。此外，執行副總裁 Coleen Glessner 於 10 月 7 日（星期二）出售了 30,608 股 Emergent Biosolutions 股票，交易平均價格為 10.00 美元，總價值為 306,080.00 美元。交易完成後，該執行副總裁直接持有公司 144,319 股，估值約為 1,443,190 美元。該交易使其持股比例減少了 17.50%。有關此交易的更多細節可在官方 SEC 披露中找到。公司內部人士持有 1.20% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
</ul>
<div class="lb-trans"><ul>
<li>在市場輪換持續的情況下，關注這 4 只超買股票</li>
</ul>
</div><p>A number of research analysts recently issued reports on the stock. Zacks Research upgraded shares of Emergent Biosolutions to a &#34;hold&#34; rating in a research report on Friday, October 24th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $15.00 price target on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Weiss Ratings reissued a &#34;hold (c-)&#34; rating on shares of Emergent Biosolutions in a research note on Monday. Finally, Wall Street Zen raised Emergent Biosolutions from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday, November 30th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average target price of $15.00.</p>
<div class="lb-trans"><p>一些研究分析師最近對該股票發佈了報告。Zacks Research 在 10 月 24 日（星期五）的研究報告中將 Emergent Biosolutions 的股票評級上調至 “持有”。HC Wainwright 在 12 月 16 日（星期二）的研究報告中重申了 “買入” 評級，並設定了 15.00 美元的目標價。Weiss Ratings 在週一的研究報告中重新發布了對 Emergent Biosolutions 的 “持有（c-）” 評級。最後，Wall Street Zen 在 11 月 30 日（星期日）的研究報告中將 Emergent Biosolutions 的評級從 “買入” 上調至 “強力買入”。一位研究分析師對該股票給予了買入評級，兩位分析師對該股票給予了持有評級。根據 MarketBeat.com，該公司目前的平均評級為 “持有”，平均目標價為 15.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on EBS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 EBS 的最新報告</strong></p>
</div><h2>About Emergent Biosolutions</h2>
<div class="lb-trans"><h2>關於 Emergent Biosolutions</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.</p>
<div class="lb-trans"><p>Emergent BioSolutions 是一家全球性的專業生物製藥公司，專注於開發、生產和商業化應對公共衞生威脅的醫療對策和專業產品。該公司的產品組合包括疫苗、抗體療法和旨在保護人們免受生物、化學和新興傳染病威脅的重症護理產品。Emergent 與政府機構（包括美國國防部和生物醫學高級研究與發展局（BARDA））建立了長期合作關係，以支持國家應急準備計劃。</p>
</div><p>Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.</p>
<div class="lb-trans"><p>Emergent 產品線中的關鍵商業產品包括 BioThrax（炭疽疫苗）、ACAM2000（天花疫苗）和 Vaxchora（霍亂疫苗），以及治療性產品如 Anthrasil（炭疽免疫球蛋白）和用於阿片類藥物過量逆轉的納洛酮鼻噴霧劑 Narcan。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Emergent Biosolutions</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Emergent Biosolutions</li>
<li>在 1 月 1 日前投資 1000 美元於此股票 [不是 NVDA]</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓為戰爭做準備</li>
<li>奇特的水晶金屬性能超越硅達 100 倍</li>
<li>來自奇怪新 “AI 燃料” 的 33000% 繁榮？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVCUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EBS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Emergent Biosolutions Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元於 Emergent Biosolutions 嗎？</h2>
</div><p>Before you consider Emergent Biosolutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Emergent Biosolutions 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Emergent Biosolutions 並不在名單上。</p>
</div><p>While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Emergent Biosolutions 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Assenagon Asset Management S.A. 在 Emergent Biosolutions Inc. $EBS 中持有價值 49.8 萬美元的股票頭寸